Inventiva announces the positive recommendation of the 4th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH

Ads

You May Also Like

Global Precision Medicine Market Report 2017-2026

Dublin, Oct. 24, 2017 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market" report has ...

Calithera Biosciences Reports Second Quarter 2016 Financial Results and Recent Highlights

Two novel agents that modulate tumor and immune cell metabolism in clinical developmentCalithera to ...

Orion Group Financial Statement documents 2017 and Corporate Governance Statement published

ORION CORPORATION           STOCK EXCHANGE RELEASE         26 FEBRUARY 2018 at 13.00 EET                       Orion Group ...